Cargando…

The Omicron subvariant BA.2: Birth of a new challenge during the COVID-19 pandemic

Detalles Bibliográficos
Autores principales:	Rahimi, Farid, Talebi Bezmin Abadi, Amin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IJS Publishing Group Ltd. Published by Elsevier Ltd. 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837492/ https://www.ncbi.nlm.nih.gov/pubmed/35167986 http://dx.doi.org/10.1016/j.ijsu.2022.106261

Ejemplares similares

Emergence of the Omicron SARS-CoV-2 subvariants during the COVID-19 pandemic
por: Rahimi, Farid, et al.
Publicado: (2022)

Implications of the SARS-CoV-2 subvariants BA.4 and BA.5
por: Rahimi, Farid, et al.
Publicado: (2022)

Detection of the XE subvariant of SARS-CoV-2: A perspective
por: Rahimi, Farid, et al.
Publicado: (2022)

‘The end’ – or is it? Emergence of SARS-CoV-2 EG.5 and BA.2.86 subvariants
por: Rahimi, Farid, et al.
Publicado: (2023)

The Ukrainian refugee crisis and the COVID-19 pandemic in Europe
por: Rahimi, Farid, et al.
Publicado: (2022)

Challenges of managing the asymptomatic carriers of SARS-CoV-2
por: Rahimi, Farid, et al.
Publicado: (2020)

Highly contagious but less severe COVID-19 caused by new SARS-CoV-2 sublineages may abate the pandemic
por: Rahimi, Farid, et al.
Publicado: (2022)

COVID-19 and science diplomacy
por: Rahimi, Farid, et al.
Publicado: (2022)

WHO prequalified tocilizumab and vaccine boosters against COVID-19
por: Rahimi, Farid, et al.
Publicado: (2022)

Hybrid SARS-CoV-2 variants
por: Rahimi, Farid, et al.
Publicado: (2022)

The 2022 monkeypox outbreak: Lessons from the 640 cases in 36 countries
por: Rahimi, Farid, et al.
Publicado: (2022)

Protection against Reinfection with the Omicron BA.2.75 Subvariant
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

Is Omicron the last SARS-CoV-2 Variant of Concern?
por: Rahimi, Farid, et al.
Publicado: (2022)

Omicron: A highly transmissible SARS-CoV-2 variant
por: Rahimi, Farid, et al.
Publicado: (2022)

Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75
por: Takashita, Emi, et al.
Publicado: (2022)

Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination
por: Chalkias, Spyros, et al.
Publicado: (2022)

Immediate countermeasures against the monkeypox outbreak
por: Rahimi, Farid, et al.
Publicado: (2022)

Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5
por: Arora, Prerna, et al.
Publicado: (2022)

A Commentary on “Omicron SARS-CoV-2 variant: Reasons of emergence and lessons learnt” (Int J Surg 2022;97:106198) Contact-tracing and global vaccine equity: Crucial responses to emergence of the Omicron SARS-CoV-2 variant
por: Rahimi, Farid, et al.
Publicado: (2022)

Tackling the COVID-19 Pandemic
por: Rahimi, Farid, et al.
Publicado: (2020)

Omicron subvariants escape antibodies elicited by vaccination and BA.2.2 infection
por: Yao, Lin, et al.
Publicado: (2022)

In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6
por: Takashita, Emi, et al.
Publicado: (2022)

Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
por: Arora, Prerna, et al.
Publicado: (2022)

Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants
por: Takashita, Emi, et al.
Publicado: (2022)

Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5
por: Hachmann, Nicole P., et al.
Publicado: (2022)

Transparency and information sharing could help abate the COVID-19 pandemic
por: Rahimi, Farid, et al.
Publicado: (2020)

Comparative neutralisation profile of SARS-CoV-2 omicron subvariants BA.2.75 and BA.5
por: Tan, Chee-Wah, et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
por: Qu, Panke, et al.
Publicado: (2022)

Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6
por: Dijokaite-Guraliuc, Aiste, et al.
Publicado: (2022)

Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6
por: Hachmann, Nicole P., et al.
Publicado: (2022)

Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants
por: Altarawneh, Heba N., et al.
Publicado: (2022)

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
por: Takashita, Emi, et al.
Publicado: (2022)

Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation
por: Wang, Qian, et al.
Publicado: (2022)

Co-infection with SARS-CoV-2 omicron BA.1 and BA.2 subvariants in a non-vaccinated woman
por: Vatteroni, Maria Linda, et al.
Publicado: (2022)

Omicron Subvariants, Including BA.4 and BA.5, Substantially Preserve T Cell Epitopes of Ancestral SARS-CoV-2
por: Park, Kyemyung, et al.
Publicado: (2022)

Cases of BA.2.75 and recent BA.2.75.2 subvariant of Omicron are increasing in India: Is it alarming at the global level?
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

The Mu strain: the last but not least circulating ‘variant of interest’ potentially affecting the COVID-19 pandemic
por: Rahimi, Farid, et al.
Publicado: (2021)

Comment on “Gastric cancer and family history”
por: Abadi, Amin Talebi Bezmin
Publicado: (2017)

Implications of the Emergence of a New Variant of SARS-CoV-2, VUI-202012/01
por: Rahimi, Farid, et al.
Publicado: (2021)

Modelling the impact of the Omicron BA.5 subvariant in New Zealand
por: Lustig, Audrey, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tme8oa1na8v022odrjg741mv4s